Skip to main content
Top
Published in: Lung 6/2010

01-12-2010

Fcγ Receptor IIIb (CD16b) Polymorphisms are Associated with Susceptibility to Idiopathic Pulmonary Fibrosis

Authors: Stylianos Bournazos, Irini Bournazou, John T. Murchison, William A. Wallace, Pauline McFarlane, Nikhil Hirani, A. John Simpson, Ian Dransfield, Simon P. Hart

Published in: Lung | Issue 6/2010

Login to get access

Abstract

An excess of neutrophils in the alveoli and lung interstitium has been described in idiopathic pulmonary fibrosis (IPF). Engagement of neutrophil Fcγ receptors with IgG complexes may contribute to the pathogenesis of IPF. The neutrophil FcγRIIIb receptor occurs in two codominantly expressed allelic variants, NA1 and NA2, which exhibit different binding affinities for IgG1 and IgG3 subclasses. The aim of this study was to investigate whether FcγRIIIb genotype is associated with IPF susceptibility or disease progression. In a case-control study we compared the distribution of FcγRIIIb NA1/2 polymorphisms in 142 patients with IPF and in 218 controls using allele-specific PCR amplification. Significant skewing in the distribution of FcγRIIIb genotypes was observed between patients with IPF and control subjects. In the IPF cohort, there was higher frequency of the NA1/NA1 genotype (0.19 vs. 0.07), and lower NA2/NA2 frequency (0.31 vs. 0.50; χ2 = 17.71, df = 2, P < 0.001). The overall frequency of the NA1 allele was increased in IPF patients compared to controls (0.44 vs. 0.29; P < 0.0001, odds ratio [OR] = 1.93, 95% confidence interval [CI] = 1.42–2.64). Heterozygotes and homozygotes of the NA1 allele were at higher risk of developing IPF (OR = 2.19, 95% CI = 1.40–3.41, P = 0.0005), whereas the NA2 allele was protective against IPF (OR = 0.34, 95% CI = 0.17–0.65, P = 0.0014). There was no association of FcγRIIIb genotype with disease progression as assessed by serial lung function measurements. FcγRIIIb NA1/2 polymorphisms are associated with IPF disease susceptibility. These results support a role for immunological mechanisms contributing to IPF pathogenesis.
Literature
1.
go back to reference Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722–1727PubMed Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722–1727PubMed
2.
go back to reference Bellon B, Bernaudin JF, Mandet C, Chamak B, Kuhn J, Druet P (1982) Immune complex-mediated lung injury produced by horseradish peroxidase (HRP) and anti-HRP antibodies in rats. Am J Pathol 107:16–24PubMed Bellon B, Bernaudin JF, Mandet C, Chamak B, Kuhn J, Druet P (1982) Immune complex-mediated lung injury produced by horseradish peroxidase (HRP) and anti-HRP antibodies in rats. Am J Pathol 107:16–24PubMed
3.
go back to reference Ward PA (1979) Immune complex injury of the lung. Am J Pathol 97:85–92PubMed Ward PA (1979) Immune complex injury of the lung. Am J Pathol 97:85–92PubMed
4.
go back to reference Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE (1994) Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 49:218–224CrossRefPubMed Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE (1994) Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 49:218–224CrossRefPubMed
5.
go back to reference Dall’Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S (1988) Study of immune complexes in bronchoalveolar lavage fluids. Respiration 54(Suppl 1):36–41CrossRefPubMed Dall’Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S (1988) Study of immune complexes in bronchoalveolar lavage fluids. Respiration 54(Suppl 1):36–41CrossRefPubMed
6.
go back to reference Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE (1978) Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 298:353–357CrossRefPubMed Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE (1978) Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 298:353–357CrossRefPubMed
7.
go back to reference Gelb AF, Dreisen RB, Epstein JD, Silverthorne JD, Bickel Y, Fields M, Border WA, Taylor CR (1983) Immune complexes, gallium lung scans, and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis. Chest 84:148–153CrossRefPubMed Gelb AF, Dreisen RB, Epstein JD, Silverthorne JD, Bickel Y, Fields M, Border WA, Taylor CR (1983) Immune complexes, gallium lung scans, and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis. Chest 84:148–153CrossRefPubMed
8.
go back to reference Haslam PL, Thompson B, Mohammed I, Townsend PJ, Hodson ME, Holborow EJ, Turner-Warwick M (1979) Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 37:381–390PubMed Haslam PL, Thompson B, Mohammed I, Townsend PJ, Hodson ME, Holborow EJ, Turner-Warwick M (1979) Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 37:381–390PubMed
9.
go back to reference Martinet Y, Haslam PL, Turner-Warwick M (1984) Clinical significance of circulating immune complexes in ‘lone’ cryptogenic fibrosing alveolitis and those with associated connective tissue disorders. Clin Allergy 14:491–497CrossRefPubMed Martinet Y, Haslam PL, Turner-Warwick M (1984) Clinical significance of circulating immune complexes in ‘lone’ cryptogenic fibrosing alveolitis and those with associated connective tissue disorders. Clin Allergy 14:491–497CrossRefPubMed
10.
go back to reference Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ueda R, Bandoh S, Kamei T, Nishioka M, Ishida T, Takahara J (2000) Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 178:171–179CrossRefPubMed Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ueda R, Bandoh S, Kamei T, Nishioka M, Ishida T, Takahara J (2000) Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 178:171–179CrossRefPubMed
11.
go back to reference Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Bandou S, Ueda Y, Takahara J (2000) Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 67:397–401CrossRefPubMed Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Bandou S, Ueda Y, Takahara J (2000) Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 67:397–401CrossRefPubMed
12.
go back to reference Takahashi T, Wada I, Ohtsuka Y, Munakata M, Homma Y, Kuroki Y (2007) Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis. Respirology 12:642–653CrossRefPubMed Takahashi T, Wada I, Ohtsuka Y, Munakata M, Homma Y, Kuroki Y (2007) Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis. Respirology 12:642–653CrossRefPubMed
13.
go back to reference Gadek J, Hunninghake G, Zimmerman R, Kelman J, Fulmer J, Crystal RG (1979) Pathogenetic studies in idiopathic pulmonary fibrosis. Control of neutrophil migration by immune complexes. Chest 75:264–265PubMed Gadek J, Hunninghake G, Zimmerman R, Kelman J, Fulmer J, Crystal RG (1979) Pathogenetic studies in idiopathic pulmonary fibrosis. Control of neutrophil migration by immune complexes. Chest 75:264–265PubMed
14.
go back to reference Hunninghake GW, Gadek JE, Lawley TJ, Crystal RG (1981) Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 68:259–269CrossRefPubMed Hunninghake GW, Gadek JE, Lawley TJ, Crystal RG (1981) Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 68:259–269CrossRefPubMed
15.
go back to reference Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WAH, Wells AU, Whyte MK, Wilsher ML (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl 5):v1–v58PubMed Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WAH, Wells AU, Whyte MK, Wilsher ML (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl 5):v1–v58PubMed
16.
go back to reference American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304 American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304
17.
go back to reference Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I (2009) Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol 182:8026–8036CrossRefPubMed Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I (2009) Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol 182:8026–8036CrossRefPubMed
18.
go back to reference Green JM, Schreiber AD, Brown EJ (1997) Role for a glycan phosphoinositol anchor in Fcγ receptor synergy. J Cell Biol 139:1209–1217CrossRefPubMed Green JM, Schreiber AD, Brown EJ (1997) Role for a glycan phosphoinositol anchor in Fcγ receptor synergy. J Cell Biol 139:1209–1217CrossRefPubMed
19.
go back to reference Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6:173–182CrossRefPubMed Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6:173–182CrossRefPubMed
20.
go back to reference Bournazos S, Woof JM, Hart SP, Dransfield I (2009) Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 157:244–254CrossRefPubMed Bournazos S, Woof JM, Hart SP, Dransfield I (2009) Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 157:244–254CrossRefPubMed
21.
go back to reference Salmon JE, Edberg JC, Kimberly RP (1990) Fcγ receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest 85:1287–1295CrossRefPubMed Salmon JE, Edberg JC, Kimberly RP (1990) Fcγ receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest 85:1287–1295CrossRefPubMed
22.
go back to reference Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM (1989) Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 84:1688–1691CrossRefPubMed Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM (1989) Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 84:1688–1691CrossRefPubMed
23.
go back to reference Ory PA, Clark MR, Talhouk AS, Goldstein IM (1991) Transfected NA1 and NA2 forms of human neutrophil Fc receptor III exhibit antigenic and structural heterogeneity. Blood 77:2682–2687PubMed Ory PA, Clark MR, Talhouk AS, Goldstein IM (1991) Transfected NA1 and NA2 forms of human neutrophil Fc receptor III exhibit antigenic and structural heterogeneity. Blood 77:2682–2687PubMed
24.
go back to reference De Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE (1995) Neutrophil FcγRIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 86:2403–2413PubMed De Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE (1995) Neutrophil FcγRIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 86:2403–2413PubMed
25.
go back to reference Bournazos S, Rennie J, Hart S, Fox KAA, Dransfield I (2008) Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status. Arterioscler Thromb Vasc Biol 28:1491–1498CrossRefPubMed Bournazos S, Rennie J, Hart S, Fox KAA, Dransfield I (2008) Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status. Arterioscler Thromb Vasc Biol 28:1491–1498CrossRefPubMed
26.
go back to reference Trounstine ML, Peltz GA, Yssel H, Huizinga TW, Von dem Borne AE, Spits H, Moore KW (1990) Reactivity of cloned, expressed human FcγRIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of FcγRIII. Int Immunol 2:303–310CrossRefPubMed Trounstine ML, Peltz GA, Yssel H, Huizinga TW, Von dem Borne AE, Spits H, Moore KW (1990) Reactivity of cloned, expressed human FcγRIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of FcγRIII. Int Immunol 2:303–310CrossRefPubMed
27.
go back to reference Hanson D, Winterbauer RH, Kirtland SH, Wu R (1995) Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108:305–310CrossRefPubMed Hanson D, Winterbauer RH, Kirtland SH, Wu R (1995) Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108:305–310CrossRefPubMed
28.
go back to reference Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU (2003) Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168:531–537CrossRefPubMed Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU (2003) Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168:531–537CrossRefPubMed
29.
go back to reference Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, Martinez FJ (2003) Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168:543–548CrossRefPubMed Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, Martinez FJ (2003) Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168:543–548CrossRefPubMed
32.
go back to reference Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F (2000) Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med 162:755–758PubMed Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F (2000) Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med 162:755–758PubMed
33.
go back to reference Checa M, Ruiz V, Montaño M, Velázquez-Cruz R, Selman M, Pardo A (2008) MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 124:465–472CrossRefPubMed Checa M, Ruiz V, Montaño M, Velázquez-Cruz R, Selman M, Pardo A (2008) MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 124:465–472CrossRefPubMed
34.
go back to reference Molina-Molina M, Xaubet A, Li X, Abdul-Hafez A, Friderici K, Jernigan K, Fu W, Ding Q, Pereda J, Serrano-Mollar A, Casanova A, Rodríguez-Becerra E, Morell F, Ancochea J, Picado C, Uhal BD (2008) Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur Respir J 32:1004–1008CrossRefPubMed Molina-Molina M, Xaubet A, Li X, Abdul-Hafez A, Friderici K, Jernigan K, Fu W, Ding Q, Pereda J, Serrano-Mollar A, Casanova A, Rodríguez-Becerra E, Morell F, Ancochea J, Picado C, Uhal BD (2008) Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur Respir J 32:1004–1008CrossRefPubMed
35.
go back to reference Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, Taniguchi H, Kubo M, Kamatani N, Nakamura Y, Group PCS (2008) A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 45:654–656CrossRefPubMed Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, Taniguchi H, Kubo M, Kamatani N, Nakamura Y, Group PCS (2008) A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 45:654–656CrossRefPubMed
36.
go back to reference Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM (2001) Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 163:1432–1436PubMed Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM (2001) Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 163:1432–1436PubMed
37.
go back to reference Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV (2004) Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 34:126–129CrossRefPubMed Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV (2004) Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 34:126–129CrossRefPubMed
38.
go back to reference Selman M, Lin HM, Montaño M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, Lang CM, Pardo A, Phelps DS, Floros J (2003) Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 113:542–550CrossRefPubMed Selman M, Lin HM, Montaño M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, Lang CM, Pardo A, Phelps DS, Floros J (2003) Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 113:542–550CrossRefPubMed
39.
go back to reference Vasakova M, Striz I, Dutka J, Slavcev A, Jandova S, Kolesar L, Sulc J (2007) Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. Respir Med 101:944–950CrossRefPubMed Vasakova M, Striz I, Dutka J, Slavcev A, Jandova S, Kolesar L, Sulc J (2007) Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. Respir Med 101:944–950CrossRefPubMed
40.
go back to reference Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J (2006) Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens 67:229–232CrossRefPubMed Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J (2006) Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens 67:229–232CrossRefPubMed
41.
go back to reference Whittington HA, Freeburn RW, Godinho SIH, Egan J, Haider Y, Millar AB (2003) Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun 4:258–264CrossRefPubMed Whittington HA, Freeburn RW, Godinho SIH, Egan J, Haider Y, Millar AB (2003) Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun 4:258–264CrossRefPubMed
42.
go back to reference Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, Campistol JM, Mullol J, Picado C (2003) Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:431–435CrossRefPubMed Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, Campistol JM, Mullol J, Picado C (2003) Transforming growth factor-β1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:431–435CrossRefPubMed
43.
go back to reference Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M, De Silvestri A, Patelli M, Martinetti M, Cuccia M, Poletti V, Pozzi E, Luisetti M (2003) Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:330–334CrossRefPubMed Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M, De Silvestri A, Patelli M, Martinetti M, Cuccia M, Poletti V, Pozzi E, Luisetti M (2003) Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:330–334CrossRefPubMed
Metadata
Title
Fcγ Receptor IIIb (CD16b) Polymorphisms are Associated with Susceptibility to Idiopathic Pulmonary Fibrosis
Authors
Stylianos Bournazos
Irini Bournazou
John T. Murchison
William A. Wallace
Pauline McFarlane
Nikhil Hirani
A. John Simpson
Ian Dransfield
Simon P. Hart
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Lung / Issue 6/2010
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-010-9262-3

Other articles of this Issue 6/2010

Lung 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.